Share price · NKTR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NKTR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Oct 2026-7.3%
- 1 Oct 2026-22.4%
- 22 Sep 2026-8.8%
Nothing announced by NKTR that day or the session before.
- 3 Sep 2026+5.0%
Nothing announced by NKTR that day or the session before.
- 2 Jul 2026+10.3%
Nothing announced by NKTR that day or the session before.
- 30 Jun 2026+6.8%
Nothing announced by NKTR that day or the session before.
- 20 Apr 2026+18.3%
- 11 Feb 2026+18.5%
- 10 Feb 2026+51.1%
- 22 Dec 2025-7.2%
Nothing announced by NKTR that day or the session before.
Share of unusual movement by asset
For each asset, the share of NKTR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-2 mutein (Treg-selective)Protein / enzyme therapeutic | Atopic DermatitisAlopecia Areata | |
| Preclinical / Unstaged | IL-15 receptorOther | Bladder Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $9.4M | $44M | $35M+ $580M short-term inv. | $56M-$72M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $10M | $39M | $39M+ $645M short-term inv. | $41M-$76M operating cash flow | report ↗ |
| 2026-Q1 | $11M | $36M | $732M+ $419M short-term inv. | $45M-$44M operating cash flow | report ↗ |
| 2025-Q3 | $12M | $27M | $41M+ $229M short-term inv. | $36M-$49M operating cash flow | report ↗ |
| 2025-Q2 | $11M | $30M | $43M+ $133M short-term inv. | $42M-$46M operating cash flow | report ↗ |
| 2025-Q1 | $10M | $30M | $39M+ $180M short-term inv. | $51M-$49M operating cash flow | report ↗ |
| 2024-Q3 | $24M | $35M | $30M+ $214M short-term inv. | $37M-$44M operating cash flow | report ↗ |
| 2024-Q2 | $23M | $30M | $28M+ $243M short-term inv. | $52M-$38M operating cash flow | report ↗ |
| 2024-Q1 | $22M | $27M | $49M+ $241M short-term inv. | $37M-$48M operating cash flow | report ↗ |
| 2023-Q3 | $24M | $24M | $65M+ $308M short-term inv. | $46M-$42M operating cash flow | report ↗ |
| 2023-Q2 | $21M | $30M | $51M+ $359M short-term inv. | $51M-$52M operating cash flow | report ↗ |
| 2023-Q1 | $22M | $30M | $77M+ $380M short-term inv. | $137M-$52M operating cash flow | report ↗ |
| 2022-Q3 | $24M | $34M | $106M+ $441M short-term inv. | $59M-$83M operating cash flow | report ↗ |
| 2022-Q2 | $22M | $43M | $78M+ $542M short-term inv. | $159M-$75M operating cash flow | report ↗ |
| 2022-Q1 | $25M | $107M | $68M+ $599M short-term inv. | $90M-$88M operating cash flow | report ↗ |
| 2021-Q4 | $25M | $100M | $25M+ $709M short-term inv. | $146M-$152M operating cash flow | report ↗ |
| 2021-Q3 | $25M | $104M | $54M+ $867M short-term inv. | $130M-$101M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $55M | $117M | $15M+ $231M short-term inv. | $41M-$209M operating cash flow | report ↗ |
Nektar Therapeutics reported full-year 2025 revenue of $55.23M, down 43.9% YoY, with R&D expense of $117.33M, down 3.0% YoY. Cash and equivalents were $15.12M, while cash and investments in marketable securities totaled $245.8M at December 31, 2025, and the company recorded a net loss of $164.08M for the year.
The company highlighted transformative Phase 2b results for rezpegaldesleukin in atopic dermatitis and alopecia areata, with 52-week maintenance data reported in early 2026 and a Phase 3 program in atopic dermatitis expected to start in June 2026. A February 2026 public offering raised $460M in gross proceeds, and a research collaboration with UCSF was established for NKTR-0165 in multiple sclerosis. Upcoming milestones include topline data from the REZOLVE-AA treatment extension in April 2026 and additional readouts through 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $98M | $121M | $44M+ $211M short-term inv. | $30M-$176M operating cash flow | report ↗ |
| 2023-FY | $90M | $114M | $35M+ $268M short-term inv. | $69M-$193M operating cash flow | report ↗ |
| 2022-FY | $92M | $218M | $88M+ $417M short-term inv. | $92M-$304M operating cash flow | report ↗ |
| 2021-FY | $102M | $400M | $25M+ $709M short-term inv. | $131M-$413M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Zalevsky Jonathan · Chief R&D Officer | Open-market sale | 192 | $35.85 | $7K | Form 4 |
| 2026-11-17 | ROBIN HOWARD W · director, President & CEO | Open-market sale | 429 | $35.85 | $15K | Form 4 |
| 2026-09-23 | Ajer Jeffrey Robert · director | Award / grant | 2,000 | — | — | Form 4 |
| 2026-09-23 | Brainard Diana · director | Award / grant | 2,000 | — | — | Form 4 |
| 2026-09-23 | CHESS ROBERT · director | Award / grant | 2,000 | — | — | Form 4 |
| 2026-09-23 | GREER R SCOTT · director | Award / grant | 2,000 | — | — | Form 4 |
| 2026-09-23 | WHITFIELD ROY A · director | Award / grant | 2,000 | — | — | Form 4 |
| 2026-09-23 | Ajer Jeffrey Robert · director | Award / grant (derivative) | 4,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 207 reporting institutions held 26.7M shares ($1.9B, 78.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 4,303,188 | $309.6M |
| 2 | BVF INC/IL | 2,559,595 | $184.2M |
| 3 | Two Seas Capital LP | 1,959,178 | $141.0M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,197,055 | $86.1M |
| 5 | TWO SIGMA INVESTMENTS, LP | 930,741 | $67.0M |
| 6 | Prosight Management, LP | 735,000 | $52.9M |
| 7 | BlackRock, Inc. | 692,650 | $49.8M |
| 8 | MORGAN STANLEY | 659,387 | $47.4M |
| 9 | ARMISTICE CAPITAL, LLC | 578,000 | $41.6M |
| 10 | Invesco Ltd. | 567,458 | $40.8M |
| 11 | CITADEL ADVISORS LLC | 513,531 | $36.9M |
| 12 | Sofinnova Investments, Inc. | 509,546 | $36.7M |
| 13 | Woodline Partners LP | 415,335 | $29.9M |
| 14 | MILLENNIUM MANAGEMENT LLC | 404,277 | $29.1M |
| 15 | EMERALD ADVISERS, LLC | 394,604 | $28.4M |